PanGIA Biotech, a pioneer in liquid biopsy technology, has announced its first international partnership, collaborating with Canary Oncoceutics (Canary Oncoceutics, Inc., Phoenix, AZ, and Canary Oncoceutics India, Tamil Nadu). This collaboration introduces the PanGIA Prostate Assay, the world’s first artificial intelligence (AI)-integrated urine-based liquid biopsy for prostate cancer detection, marking its commercial debut in India.

PanGIA Biotech is actively advancing its R&D pipeline, targeting ten additional cancers including lung, pancreatic, ovarian, and breast. The company is also focused on validating its multi-cancer assay and expanding its global impact through continued innovation, offering long-term growth potential for partners.

"Launching our patented PanGIA Prostate Assay in India marks an important milestone for our company and healthcare innovation. This non-invasive, accurate, and culturally sensitive diagnostic tool is poised to enhance early prostate cancer detection and improve patient outcomes," said Holly Magliochetti, CEO of PanGIA Biotech. "Partnering with Canary Oncoceutics enables us to bring life-changing technology to a population in need, reinforcing our commitment to saving lives, changing lives, and giving back by advancing healthcare equity."

The PanGIA platform is a transformative solution for detecting, monitoring, and managing diseases, including cancers as early as Stage 1. Powered by machine learning, this urine-based platform profiles biomolecular patterns to deliver accurate diagnostic insights.